Palatin Amends S-1, Reveals Pattern of Dilutive Capital Raises

TL;DR

**PTN's S-1/A confirms a relentless, dilutive capital raise strategy, signaling ongoing financial strain and a high-risk bet for common shareholders.**

AI Summary

Palatin Technologies, Inc. (PTN) filed an S-1/A on October 1, 2025, primarily to provide an executed auditor consent as Exhibit 23.2, with no additional securities being registered. The filing details a series of private placements and warrant inducement exercises over the past three years, indicating a consistent strategy of capital raising through dilutive means. On June 10, 2025, PTN issued 3,400 shares of Series D Convertible Preferred Stock and warrants for 123,636 common shares at a combined price of $5.50. Earlier, on February 6, 2025, the company issued Series E common stock purchase warrants for 93,760 shares at a combined offering price of $50.00. In December 2024, PTN received approximately $3.4 million from warrant exercises by adjusting the exercise price to $43.75 for 78,153 shares. Similarly, in June 2024, the company generated approximately $6.1 million from warrant exercises at a reduced price of $94.00 per share for 64,666 shares. These transactions highlight a reliance on equity financing and warrant adjustments to secure capital, often involving significant dilution for existing shareholders.

Why It Matters

This S-1/A filing, while an exhibits-only amendment, underscores Palatin Technologies' ongoing reliance on dilutive financing methods, which is critical for investors to understand. The repeated use of private placements and warrant inducement exercises, such as the $3.4 million raised in December 2024 and $6.1 million in June 2024, suggests a continuous need for capital that could significantly impact shareholder value. For employees, sustained capital raises might signal operational stability but also potential pressure to meet development milestones. Customers and the broader market will watch if this financing strategy translates into successful product development and commercialization, especially given the competitive landscape in the biotech sector where larger players like Pfizer and Johnson & Johnson have vast R&D budgets.

Risk Assessment

Risk Level: high — The risk level is high due to the company's consistent and significant reliance on dilutive financing activities, including multiple private placements and warrant inducement exercises over the past three years. For example, the issuance of 3,400 shares of Series D Convertible Preferred Stock and warrants for 123,636 common shares on June 10, 2025, and the Series E common stock purchase warrants for 93,760 shares on February 6, 2025, indicate a continuous need for capital that could severely dilute existing common shareholders.

Analyst Insight

Investors should exercise extreme caution and thoroughly evaluate PTN's long-term financial viability and product pipeline given the persistent dilutive financing. Consider the impact of future equity raises on per-share value and assess if the company's clinical progress justifies the ongoing dilution before making any investment decisions.

Key Numbers

• $3.4 million — Gross proceeds from warrant exercise (Received in December 2024 by adjusting exercise price to $43.75 for 78,153 shares)
• $6.1 million — Gross proceeds from warrant exercise (Received in June 2024 by lowering exercise price to $94.00 per share for 64,666 shares)
• 3,400 — Shares of Series D Convertible Preferred Stock (Issued in private placement on June 10, 2025)
• 123,636 — Shares of Common Stock underlying Series I warrants (Issued in private placement on June 10, 2025)
• $5.50 — Combined offering price (For Series D Preferred Stock and Series I warrants on June 10, 2025)
• 93,760 — Shares of Common Stock underlying Series E warrants (Issued in private placement on February 6, 2025)
• $50.00 — Combined offering price (For Series E warrants and accompanying shares/pre-funded warrants on February 6, 2025)
• 36,630 — Shares of Common Stock underlying warrants (Issued in private placement on January 29, 2024)
• $273.00 — Combined offering price (For warrants and accompanying shares on January 29, 2024)
• $15,000,000 — Gross proceeds from Series B and C Preferred Stock offering (Issued on May 12, 2022, but later redeemed for $15,750,000)

Key Players & Entities

• PALATIN TECHNOLOGIES INC (company) — Registrant
• Stephen T. Wills (person) — Executive Vice President, Chief Financial Officer and Chief Operating Officer
• Faith L. Charles, Esq. (person) — Counsel at Thompson Hine LLP
• Thompson Hine LLP (company) — Legal counsel for the registrant
• A.G.P./Alliance Global Partners (company) — Lead placement agent for February 2025 private placement
• Laidlaw & Company (UK) Ltd. (company) — Co-placement agent for February 2025 private placement
• H.C. Wainwright & Co., LLC (company) — Exclusive placement agent for January 2024 and October 2023 private placements
• SEC (regulator) — Securities and Exchange Commission
• $7,989.31 (dollar_amount) — SEC registration fee
• $103,989.31 (dollar_amount) — Total estimated expenses for the offering

FAQ

Risk Factors

• Reliance on Dilutive Financing [high — financial]: Palatin Technologies has a history of raising capital through private placements and warrant exercises, often involving adjustments to exercise prices. For example, in December 2024, they received $3.4 million by adjusting the exercise price to $43.75 for 78,153 shares, and in June 2024, they generated $6.1 million by lowering the exercise price to $94.00 per share for 64,666 shares. This reliance on dilutive equity financing can significantly dilute existing shareholders' ownership.
• Convertible Preferred Stock Issuances [medium — financial]: The company has issued convertible preferred stock, such as 3,400 shares of Series D Convertible Preferred Stock on June 10, 2025, alongside warrants. These instruments can convert into common stock, leading to further dilution for common shareholders upon conversion.
• Warrant Inducement and Exercise Programs [medium — financial]: Palatin Technologies has engaged in warrant inducement and exercise programs, such as issuing Series E common stock purchase warrants for 93,760 shares on February 6, 2025, at a combined offering price of $50.00. These programs are designed to raise capital but inherently increase the number of outstanding shares.

Industry Context

Palatin Technologies operates in the biotechnology and pharmaceutical sector, focusing on developing treatments for diseases. This industry is characterized by high research and development costs, long development cycles, and significant regulatory hurdles. Companies often rely on external financing, including equity offerings and partnerships, to fund their operations and clinical trials.

Regulatory Implications

As a publicly traded company, Palatin Technologies is subject to SEC regulations and reporting requirements. The S-1/A filing itself is a regulatory document. Any future capital raises or significant corporate actions will require adherence to these regulations, including disclosure requirements to protect investors.

What Investors Should Do

1. Monitor future capital raises for the impact on share dilution and the company's cash runway.
2. Analyze the terms of any new warrant issuances or preferred stock offerings to understand potential future dilution.
3. Evaluate the company's progress in its drug development pipeline, as this is the primary driver of long-term value in the biotech sector.

Key Dates

• 2025-10-01: Filing of S-1/A — Primarily to file an executed auditor consent, indicating ongoing regulatory compliance and administrative updates to prior filings.
• 2025-06-10: Issuance of Series D Convertible Preferred Stock and Warrants — Raised capital through a private placement involving convertible preferred stock and warrants, a dilutive financing strategy.
• 2025-02-06: Issuance of Series E Common Stock Purchase Warrants — Further capital raising through the issuance of warrants, contributing to potential future dilution.
• 2024-12-01: Warrant Exercise and Capital Raise — Generated $3.4 million through warrant exercises by adjusting the exercise price, highlighting reliance on this capital source.
• 2024-06-01: Warrant Exercise and Capital Raise — Generated $6.1 million through warrant exercises at a reduced price, demonstrating a pattern of capital generation via warrant adjustments.
• 2022-05-12: Series B and C Preferred Stock Offering — Raised $15,000,000, though later redeemed for $15,750,000, indicating a significant capital event and subsequent repayment.

Glossary

S-1/A

An amended registration statement filed with the SEC, used to update or correct information in a previously filed S-1 registration statement. (This filing is an amendment to Palatin Technologies' registration statement, primarily for administrative purposes like filing an auditor's consent.)

Auditor Consent

A letter from the company's independent auditor granting permission for their name and audit report to be included in a company's SEC filings. (The S-1/A filing's main purpose was to provide this consent, a standard requirement for registration statements.)

Private Placement

The sale of securities to a select group of investors, rather than through a public offering. (Palatin Technologies has utilized private placements to raise capital, as seen with the Series D Convertible Preferred Stock issuance.)

Warrants

A security that gives the holder the right, but not the obligation, to purchase a company's stock at a predetermined price (exercise price) within a specified timeframe. (Warrants are a recurring theme in Palatin's capital raising activities, with exercises and adjustments impacting share count and capital.)

Convertible Preferred Stock

A class of preferred stock that can be converted into a specified number of common stock shares. (The issuance of Series D Convertible Preferred Stock indicates a potential future increase in common shares outstanding.)

Dilution

The reduction in the ownership percentage of a shareholder that occurs when a company issues new shares. (Palatin's frequent use of private placements and warrant exercises leads to significant dilution for existing common shareholders.)

Year-Over-Year Comparison

This S-1/A filing on October 1, 2025, is primarily an administrative update to include an auditor's consent, rather than a comprehensive financial update. Therefore, a direct comparison of key financial metrics like revenue growth or net income to the previous year is not possible based solely on this amendment. The filing reiterates the company's ongoing strategy of capital raising through dilutive equity instruments, a trend likely consistent with prior periods.

Key Financial Figures

• $5.50 — re sold at a combined offering price of $5.50. On February 6, 2025, we entered into
• $50.00 — offered at a combined offering price of $50.00. A.G.P./Alliance Global Partners acted
• $43.75 — uch portion of the existing warrants to $43.75. Pursuant to the letter agreement, the
• $3.4 million — gregate gross proceeds of approximately $3.4 million from the exercise of the existing warra
• $94.00 — ment to (i) lower the exercise price to $94.00 per share for the 64,666 existing warra
• $6.1 million — gregate gross proceeds of approximately $6.1 million from the exercise of the existing warra
• $273.00 — offered at a combined offering price of $273.00. H.C. Wainwright & Co., LLC acted as ex
• $106.00 — offered at a combined offering price of $106.00. H.C. Wainwright & Co., LLC acted as ex
• $1.67 — Preferred Stock had a purchase price of $1.67. The investors in the Series B Preferre
• $625.00 — of common stock at an exercise price of $625.00 per share, which expire on May 11, 2026
• $15,000,000 — rom the offering, before expenses, were $15,000,000 which was deposited in an escrow accoun
• $15,750,000 — agent for the escrow account to release $15,750,000 to the investors, comprising the total
• $750,000 — he offering of $15,000,000 and a fee of $750,000. We believe the offers, sales and issu

Filing Documents

• ptn_s1a.htm (S-1/A) — 182KB
• ptn_ex232.htm (EX-23.2) — 2KB
• 0001654954-25-011309.txt ( ) — 185KB

Other Expenses of Issuance and Distribution

Item 13. Other Expenses of Issuance and Distribution The following table sets forth all costs and expenses payable by us in connection with the sale of the securities being registered. All amounts shown are estimates except for the SEC registration fee. Amount SEC registration fee $ 7,989.31 Accountant's fees and expenses $ 20,000 Legal fees and expenses $ 75,000 Miscellaneous fees and expenses $ 1,000 Total expenses $ 103,989.31

Indemnification of Directors and Officers

Item 14. Indemnification of Directors and Officers Our Certificate of Incorporation and Bylaws require us to indemnify our directors, officers, employees and agents against the costs (including fines, judgments and attorney fees) from involvement in legal proceedings arising from their position or service, provided that the person seeking indemnification acted: in good faith; in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the corporation; and with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. The Certificate of Incorporation and Bylaws allow us to buy indemnification insurance for this purpose. Our Certificate of Incorporation provides that, to the fullest extent permissible under Delaware law, no director shall be personally liable to the corporation or its stockholders for monetary damages for breach of a fiduciary duty as a director. However, this provision does not eliminate the duty of care, and in appropriate circumstances, equitable remedies such as injunctive or other forms of non-monetary relief that will remain available under Delaware law. In addition, each director will continue to be subject to liability for (a) breach of the director's duty of loyalty to us or our stockholders, (b) acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (c) violating Section 174 of the DGCL, or (d) any transaction from which the director derived an improper personal benefit. The provision also does not affect a director's responsibilities under any other law, such as the federal securities laws or state or federal environmental laws. II-1

Recent Sales of Unregistered Securities

Item 15. Recent Sales of Unregistered Securities The following list sets forth information regarding unregistered securities sold by us within the past three years. On June 10, 2025, we entered into a securities purchase agreement with certain accredited investors, pursuant to which we issued, in a private placement, (i) an aggregate of 3,400 shares of the Company's Series D Convertible Preferred Stock, initially convertible into 61,816 shares of the Company's Common Stock and (ii) Series I Common Stock purchase warrants to purchase up to an aggregate of 123,636 shares of Common Stock. The preferred stock and Series I Common Stock purchase warrants were sold at a combined offering price of $5.50. On February 6, 2025, we entered into a securities purchase agreement with the investor named on the signature page thereto, pursuant to which we issued, in a private placement, Series E common stock purchase warrants to purchase up to 93,760 shares of common stock. The warrants and accompanying shares of common stock or pre-funded warrants (which were sold in a concurrent registered direct offering) were offered at a combined offering price of $50.00. A.G.P./Alliance Global Partners acted as lead placement agent and Laidlaw & Company (UK) Ltd., as co-placement agent in connection with such private placement. On December 13, 2024, we entered into a letter agreement with a holder of outstanding common stock purchase warrants. To induce the exercise of a portion of such existing warrants by the holder, we agreed to adjust the exercise price of such portion of the existing warrants to $43.75. Pursuant to the letter agreement, the holder agreed to exercise, for cash, the existing warrants to purchase an aggregate of 78,153 shares of common stock (which were registered under certain of our registration statements filed with the SEC) at the adjusted exercise price in exchange for our agreement to issue to the holder Series C common stock purchase warrants to purchase 78,153 s

Exhibits and Financial Statement Schedules

Item 16. Exhibits and Financial Statement Schedules The exhibits listed below are filed as part of this registration statement: Exhibit Number Description Filed Herewith Form Filing Date SEC File No. 1.1 Underwriting Agreement S-1 October 1, 2025 333-290641 3.1 Restated Certificate of Incorporation, as amended. 10-K September 27, 2013 001-15543 3.2 Certificate of Decrease of Series A Convertible Preferred Stock. 10-Q May 16, 2022 001-15543 3.3 Certificate of Amendment of Restated Certificate of Incorporation. 8-K August 31, 2022 001-15543 3.4 Amended and Restated Bylaws. 8-K September 17, 2021 001-15543 3.5 Certificate of Designation of the Rights, Powers, Preferences, Privileges, and Restrictions of the Series D Convertible Preferred Stock of Palatin Technologies, Inc. 8-K June 13, 2025 001-15543 3.6 Certificate of Amendment to Restated Certificate of Incorporation, filed with Delaware Secretary of State on August 6, 2025 8-K August 8, 2025 001-15543 4.1 Reference is made to Exhibits 3.1 through 3.4. 001-15543 4.2 Form of Pre-Funded Warrant. 8-K May 8, 2025 4.3 Form of Series F Common Warrant 8-K May 8, 2025 001-15543 4.4 Form of Series G Common Warrant 8-K May 8, 2025 001-15543 4.5 Form of Series H Common Warrant 8-K May 8, 2025 001-15543 4.6 Form of Series I Common Warrant 8-K June 13, 2025 001-15543 4.7 Form of Pre-Funded Warrant S-1 October 1, 2025 333-290641 4.8 Form of Series J Common Warrant S-1 October 1, 2025 333-290641 4.9 Form of Series K Common Warrant S-1 October 1, 2025 333-290641 4.10 Form of Underwriter Warrant to Purchase Common Stock S-1 October 1, 2025 333-290641 5.1 Opinion of Thompson Hine LLP. S-1 October 1, 2025 333-290641 10.1 1996 Stock Option Plan, as amended. 10-K September 28, 2009 001-15543 10.2 Form of Option Certificate (Incentive Option) Under the 2005 Stock Plan. 8-K September 21, 2005

Undertakings

Item 17. Undertakings (a) The undersigned registrant hereby undertakes: (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: (i) To include any prospectus required by section 10(a)(3) of the Securities Act; (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in the volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement; and (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; provided, however , that the undertakings set forth in paragraphs (1)(i), (1)(ii) and (1)(iii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are incorporated by reference into this registration statement or are contained in a form of prospectus filed pursuant to Rule 424(b) that is part of this registration statement. (2) That, for

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Township of Cranbury, State of New Jersey, on October 1, 2025. Palatin Technologies, Inc. By: /s/Carl Spana Name: Carl Spana, Ph.D. Title: President and Chief Executive Officer Pursuant to the requirements of the Securities Act of 1933, as amended, this reg

View Full Filing

View this S-1/A filing on SEC EDGAR